Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
2
×
alzheimer's disease
2
×
biotech
boston blog main
boston top stories
2
×
boulder/denver blog main
boulder/denver top stories
cancer
2
×
clinical trials
crispr
detroit blog main
detroit top stories
eli lilly
glaxosmithkline
2
×
indiana blog main
indiana top stories
life sciences
merck
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
2
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
acceleron pharma
acid sphingomyelinase deficiency
adalimumab (humira)
aducanumab
What
bio
companies
roundup
approval
biogen’s
biopharmaceutical
black
continue
convo
debut
diamond
diamond’s
drug
earlier
failures
indication
leading
life
littered
mammoth
march
moves
nash
new
news
ohana’s
pop
price
remains
road
science
steady
strategy
street
talk
therapeutics
wall
week
Language
unset
Current search:
glaxosmithkline
×
startups
×
" boston top stories "
×
" alzheimer's disease "
×
cancer
×
abbvie
×
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More